ADMA Biologics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics or view top-rated stocks.

Wall Street analysts have given ADMA Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADMA Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ADMA Biologics saw a increase in short interest in July. As of July 30th, there was short interest totaling 13,320,000 shares, an increase of 14.2% from the July 15th total of 11,660,000 shares. Based on an average daily volume of 2,120,000 shares, the days-to-cover ratio is currently 6.3 days. Currently, 10.6% of the shares of the company are short sold.
View ADMA Biologics' Short Interest.

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ADMA Biologics.

ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Tuesday, August, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. ADMA Biologics had a negative net margin of 126.67% and a negative trailing twelve-month return on equity of 76.73%.
View ADMA Biologics' earnings history.

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMA shares have decreased by 44.2% and is now trading at $1.29.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 1 year target prices for ADMA Biologics' shares. Their forecasts range from $6.00 to $10.00. On average, they expect ADMA Biologics' share price to reach $7.00 in the next year. This suggests a possible upside of 442.6% from the stock's current price.
View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ADMA Biologics include Acumen Pharmaceuticals (ABOS), Cellectis (CLLS), Osiris Therapeutics (OSIR), Molecular Partners (MOLN), Passage Bio (PASG), Innate Pharma (IPHYF), Aerie Pharmaceuticals (AERI), TCR2 Therapeutics (TCRR), Ambrx Biopharma (AMAM), MeiraGTx (MGTX), Gritstone bio (GRTS), DBV Technologies (DBVT), Talaris Therapeutics (TALS), CEL-SCI (CVM) and Poseida Therapeutics (PSTX).
View all of ADMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (4.61%), Vanguard Group Inc. (4.38%), BlackRock Inc. (1.70%), Geode Capital Management LLC (0.82%), Millennium Management LLC (0.78%) and Group One Trading L.P. (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics.

ADMA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Northern Trust Corp, Bank of America Corp DE, Principal Financial Group Inc., Geode Capital Management LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for ADMA Biologics or view top insider-selling stocks.

ADMA stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Millennium Management LLC, GSA Capital Partners LLP, Ergoteles LLC, Simplex Trading LLC, Renaissance Technologies LLC, Parametric Portfolio Associates LLC, and Qube Research & Technologies Ltd. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics or or view top insider-buying stocks.

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $1.29.

ADMA Biologics has a market capitalization of $171.27 million and generates $42.22 million in revenue each year. The biotechnology company earns $-75,750,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

ADMA Biologics employs 407 workers across the globe.

The official website for ADMA Biologics is www.admabiologics.com.

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at (201) 478-5552 or via email at [email protected].